Photo of Julie J. Miller, MD, PhD

Julie J. Miller, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital


julie.miller@mgh.harvard.edu

Photo of Julie J. Miller, MD, PhD

Massachusetts General Hospital


julie.miller@mgh.harvard.edu

Visualize Collaborations

Julie J. Miller, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Neurology, Harvard Medical School
  • Attending Neuro-Oncologist, Neurology, Massachusetts General Hospital

HCC PROGRAM AFFILIATION

Research Abstract

I am a physician-scientist in Neuro-Oncology at Massachusetts General Hospital with a research focus on incurable gliomas. As an early career investigator, my overarching career goal is to gain insight into tumorigenic mechanisms of gliomas in order to develop novel and effective treatments for patients with these tumors. I am also highly interested in treatments that minimize long-term side effects, particularly cognitive toxicity. I aim to combine basic and translational research with clinical care, with a focus on Isocitrate dehydrogenase (IDH) mutant gliomas

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Kitagawa Y, Muzyka LD, Kobayashi A, Wetzel E, Nasser A, Miller JJ, Wakimoto H, Cahill DP. Effects of short- and long-term mutant IDH1 inhibition on radiosensitivity across genetically diverse patient-derived IDH1-mutant glioma cells. 2026; 8:vdag057. PubMed
  • Youssef G, Aquilanti E, Miller JJ, Lan Z, Lasica AB, Arrillaga-Romany I, Batchelor TT, Berger TR, Beroukhim R, Chukwueke U, Dietrich J, Forst DA, Gerstner ER, Castro LNG, Jordan JT, Mcfaline-Figueroa JR, Lee EQ, Nayak L, Nakhate V, Ospina JP, Plotkin SR, Wang N, Rhee JY, Reardon DA, Wen PY. Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant Glioma. 2025. PubMed
  • Viera M, Mount CW, Dias-Santagata D, Miller JJ, Gerstner ER. A single-institution study of the natural history of fibroblast growth factor receptor-altered gliomas. Neurooncol Pract 2025; 12:797-802. PubMed
  • Lanman TA, Gross H, Faria CM, Miller JJ, Cahill DP, Shih HA, Zarrella GV, Dietrich J, Parsons MW. Factors associated with cognitive impairment in long-term IDH-mutant glioma survivors. J. Neurooncol. 2025. PubMed
  • Tazhibi M, Grewal EP, Ramapriyan R, Richardson LGK, Vandecandelaere G, Kalaw A, Kotlarz P, Steuart SJ, Sun J, Gaffey M, Cahill DP, Miller JJ, Curry WT, Choi BD. A Review of Emerging Immunotherapeutic Strategies for IDH-Mutant Glioma. Cancers (Basel) 2025. PubMed
  • Lasica AB, Lan Z, Miller JJ, Jiao A, Pan I, Aker L, Prabhakar P, Japo J, Russ A, Westergaard C, Aquilanti E, Chukwueke U, Gonzalez Castro LN, McFaline Figueroa JR, Lee EQ, Nayak L, Beroukhim R, Batchelor TT, Cahill DP, Nakhate V, Lanman T, Pablo Ospina J, Stec N, Patel RV, Meredith DM, Bi WL, Reardon DA, Ligon KL, Huang RY, Wen PY, Youssef G. Clinical, molecular and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4. 2025. PubMed
  • Lim-Fat MJ, Bennett J, Ostrom Q, Touat M, Franceschi E, Schulte J, Bindra RS, Fangusaro J, Dhall G, Nicholson J, Jackson S, Davidson TB, Calaminus G, Robinson G, Whittle JR, Hau P, Ramaswamy V, Pajtler KW, Rudà R, Foreman NK, Hervey-Jumper SL, Das S, Dirks P, Bi WL, Huang A, Merchant TE, Fouladi M, Aldape K, Van den Bent MJ, Packer RJ, Miller JJ, Reardon DA, Chang SM, Haas-Kogan D, Tabori U, Hawkins C, Monje M, Wen PY, Bouffet E, Yeo KK. Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions. 2024. PubMed
  • Wetzel EA, Nohman AI, Hsieh AL, Reuss D, Unterberg AW, Eyüpoglu IY, Hua L, Youssef G, Wen PY, Cahill DP, Jungk C, Juratli TA, Miller JJ. A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design. J. Neurooncol. 2024. PubMed
  • Batool SM, Escobedo AK, Hsia T, Ekanayake E, Khanna SK, Gamblin AS, Zheng H, Skog J, Miller JJ, Stemmer-Rachamimov AO, Cahill DP, Balaj L, Carter BS. Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas. Nat Commun 2024; 15:7074. PubMed
  • Grewal EP, Richardson LGK, Sun J, Ramapriyan R, Martinez-Lage M, Miller JJ, Carter BS, Cahill DP, Curry WT, Choi BD. Mutant IDH modulates suppressive myeloid populations in malignant glioma. Clin Cancer Res 2024. PubMed
  • Spitzer A, Gritsch S, Nomura M, Jucht A, Fortin J, Raviram R, Weisman HR, Gonzalez Castro LN, Druck N, Chanoch-Myers R, Lee JJY, Mylvaganam R, Lee Servis R, Fung JM, Lee CK, Nagashima H, Miller JJ, Arrillaga-Romany I, Louis DN, Wakimoto H, Pisano W, Wen PY, Mak TW, Sanson M, Touat M, Landau DA, Ligon KL, Cahill DP, Suvà ML, Tirosh I. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer Cell 2024; 42:904-914.e9. PubMed
  • Nasser AM, Melamed L, Wetzel E, Chang CC, Nagashima H, Kitagawa Y, Muzyka L, Wakimoto H, Cahill DP, Miller JJ. CDKN2A/B homozygous deletion sensitizes IDH-mutant glioma to CDK4/6 inhibition. Clin Cancer Res 2024. PubMed
  • Grewal EP, Richardson LGK, Sun J, Ramapriyan R, Martinez-Lage M, Miller JJ, Cahill DP, Choi BD, Curry WT. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade. Neurosurg Focus 2024; 56:E2. PubMed
  • Numan T, Breedt LC, Maciel BAPC, Kulik SD, Derks J, Schoonheim MM, Klein M, de Witt Hamer PC, Miller JJ, Gerstner ER, Stufflebeam SM, Hillebrand A, Stam CJ, Geurts JJG, Reijneveld JC, Douw L. Regional healthy brain activity, glioma occurrence and symptomatology. Brain 2022; 145:3654-3665. PubMed
  • Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS, Bi WL, Bindra R, Cahill DP, Chang SM, Costello JF, Horbinski C, Huang RY, Jenkins RB, Ligon KL, Mellinghoff IK, Nabors LB, Platten M, Reardon DA, Shi DD, Schiff D, Wick W, Yan H, von Deimling A, van den Bent M, Kaelin WG, Wen PY. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. 2022. PubMed
  • Miller JJ. Targeting IDH-Mutant Glioma. 2022. PubMed
  • Miller JJ, Cahill DP, Arrillaga-Romany I. Enhancing demethylation-induced differentiation in IDH-mutant glioma. 2022. PubMed
  • Miller JJ, Cahill DP. MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma. 2020. PubMed
  • Richardson LG, Nieman LT, Stemmer-Rachamimov AO, Zheng XS, Stafford K, Nagashima H, Miller JJ, Kiyokawa J, Ting DT, Wakimoto H, Cahill DP, Choi BD, Curry WT. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology 2020; 9:1806662. PubMed
  • Miller JJ, Fink A, Banagis JA, Nagashima H, Subramanian M, Lee CK, Melamed L, Tummala SS, Tateishi K, Wakimoto H, Cahill DP. Sirtuin activation targets IDH-mutant tumors. 2020. PubMed
  • Nagashima H, Lee CK, Tateishi K, Higuchi F, Subramanian M, Rafferty S, Melamed L, Miller JJ, Wakimoto H, Cahill DP. Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells. 2020. PubMed
  • Miller JJ, Loebel F, Juratli TA, Tummala SS, Williams EA, Batchelor TT, Arrillaga-Romany I, Cahill DP. Accelerated progression of IDH mutant glioma after first recurrence. 2019. PubMed
Hide
Visualize Collaborations